Carisma TherapeuticsCARM
13F holders, Q1 2026 (March 31)3holders −4
1new positions
4sold out
$0.03avg. 13F price*
At the end of Q1 2026, 3 institutions reported holding Carisma Therapeutics Inc. (CARM) in their 13F filings, down 4 from Q4 2025. 1 opened new positions and 4 sold out. The largest holders were Merck & Co., Inc. ($48K), Union Bancaire Privee, UBP SA ($22) and Ascentis Independent Advisors ($6).
- Company
- Carisma Therapeutics Inc.
- CUSIP
- 14216R101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $6 |
| Exits | 4 | $4K |
All 13F filers, Q4 2025 → Q1 2026: 200 shares bought and 90,806 shares sold, net −90,606 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Merck & Co., Inc. | 0.01% | No change | 1,473,240 | $48K |
| Union Bancaire Privee, UBP SA | 0.00% | No change | 785 | $22 |
| Ascentis Independent Advisors | 0.00% | New | 200 | $6 |
"% of holder's portfolio" is CARM's weight in each manager's 13F, not the share of Carisma Therapeutics Inc. the manager owns.